Research Paper Volume 15, Issue 15 pp 7476—7495

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC

class="figure-viewer-img"

Figure 2. SETBP1 mutations determined the sensitivity to ICI treatments in melanoma. (A) ICI survival differences between SETBP1 mutated and wild-type subgroups. (B) A multivariate Cox regression analysis was performed to verify the connection between SETBP1 mutations and ICI prognosis. (C) ICI response rate differences of SETBP1 two subgroups. (D) A multivariate logistic regression analysis was performed to verify the connection between SETBP1 mutations and ICI response rate.